Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor

Area of Science:

• Oncology
• Pharmacology

Background:

• Targeted therapies for B cell malignancies are advancing.
• Bruton's tyrosine kinase (BTK) inhibitors like ibrutinib are established treatments.
• Newer, more selective BTK inhibitors are under investigation.

Purpose of the Study:

• To review the preclinical research and clinical data of acalabrutinib (ACP-196).
• To evaluate acalabrutinib as a second-generation BTK inhibitor.

Main Methods:

• Literature review of preclinical studies.
• Analysis of clinical trial data for acalabrutinib.

Main Results:

• Acalabrutinib demonstrates higher potency and selectivity compared to ibrutinib.
• Preclinical and clinical data support acalabrutinib's efficacy.

Conclusions:

• Acalabrutinib represents a significant advancement in BTK-targeted therapy for B cell malignancies.
• Its improved profile warrants further clinical investigation and application.